Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 64.64 USD 3.41% Market Closed
Market Cap: 7.9B USD
Section:
 

Relative Value

The Relative Value of one CYTK stock under the Base Case scenario is 32.93 USD. Compared to the current market price of 64.64 USD, Cytokinetics Inc is Overvalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CYTK Relative Value
Base Case
32.93 USD
Overvaluation 49%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

90.5
P/S
P/S
Price to Sales
90.5
vs History
47
vs Industry
9
Median 3Y
300.5
Median 5Y
78.2
Industry
8.2
Forward
95.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-11
Industry
24.2
Forward
-9.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-14
Median 5Y
-15.1
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-23.1
Median 5Y
-25.6
Industry
25.5
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-15.5
Median 5Y
-10.9
Industry
3.3
More Details
91.5
EV/S
EV/S
Enterprise Value to Sales
91.5
vs History
47
vs Industry
7
Median 3Y
277.2
Median 5Y
79.2
Industry
8.6
Forward
96.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-12.5
Industry
6.1
Forward
-12.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-9.6
Median 5Y
-12.2
Industry
6.6
Forward
-12.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-13.1
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-12.5
Median 5Y
-14.2
Industry
6.8
More Details
17.7
EV/IC
EV/IC
Enterprise Value to IC
17.7
vs History
31
vs Industry
14
Median 3Y
15.5
Median 5Y
14
Industry
5.7
More Details

Multiples Across Competitors

CYTK Competitors Multiples
Cytokinetics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cytokinetics Inc
NASDAQ:CYTK
7.9B USD 90.5 -10.5 -14.2 -13.9
IL
Can Fite Biopharma Ltd
TASE:CANF
159.8T ILS 58 252 055.6 -4 000 376.4 -3 925 593.8 -3 916 855.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 004 331.7 -161 617.5 -196 255.2 -194 015.7
US
Abbvie Inc
NYSE:ABBV
389.4B USD 6.5 165.8 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
173.9B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.5B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.7B USD 10 32 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.8 -528.7 -575.7 -560.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.6B USD 5.9 18.5 17.7 20
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.7 19 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.1B USD 15 1 104 148.8 180.4
P/S Multiple
Revenue Growth P/S to Growth
US
Cytokinetics Inc
NASDAQ:CYTK
Average P/S: 8 387 145.5
90.5
173%
0.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
58 252 055.6
140%
416 086.1
FR
Pharnext SCA
OTC:PNEXF
34 004 331.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 071.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Cytokinetics Inc
NASDAQ:CYTK
Average P/E: 197.5
Negative Multiple: -10.5 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 000 376.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 617.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
10%
1.8
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 104
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cytokinetics Inc
NASDAQ:CYTK
Average EV/EBITDA: 35.6
Negative Multiple: -14.2 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 925 593.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
11%
1.6
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
148.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cytokinetics Inc
NASDAQ:CYTK
Average EV/EBIT: 42
Negative Multiple: -13.9 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 916 855.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 015.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20
13%
1.5
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
180.4
N/A N/A

See Also

Summary
CYTK intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYTK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYTK stock valuation using valuation multiples.
Wall Street Estimates
CYTK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYTK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.